Roivant Cuts Multiple R&D Programs As It Takes On Pfizer’s TYK2/JAK1 Inhibitor

Sickle Cell, Dermatology And Cancer Drugs Among Discontinued Assets

 
• By Mandy Jackson
  
Digital money send, currency exchange sign. Neon futuristic transfer arrow icon. Web trade symbol. Mutual exchange of information isolated on blue background
Roivant swapped out multiple programs to conserve cash and bring in a late-stage Pfizer asset • Source: Shutterstock
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Deals

More from Business